The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Biomarkers and surrogate end points—the challenge of statistical validation
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Self-citationReporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Bokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Pepe, M. S. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh101 · Cited by 1,276
Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian d'Assignies, M., Bergh, J., Lidereau, R., Ellis, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj329 · Cited by 1,238
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
Desmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y., d'Assignies, M. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2765 · Cited by 968
Self-citationDi Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
The validation of surrogate endpoints in meta-analyses of randomized experiments
Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000) · Biostatistics · doi:10.1093/biostatistics/1.1.49 · Cited by 624
Self-citationREporting recommendations for tumor MARKer prognostic studies (REMARK)
for the Statistics Subcommittee of the NCI—EORTC Working Group on Cancer Diagnostics (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0252 · Cited by 561
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Rolski, J., Chan, A., Mackey, J., Liu, M., Pinter, T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-62 · Cited by 553
Self-citationClinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials
Sargent, D. J., Conley, B. A., Allegra, C., & Collette, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.112 · Cited by 499
Self-citationRules of evidence for cancer molecular-marker discovery and validation
Ransohoff, D. F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1322 · Cited by 498
Buyse, M., Thirion, P., Carlson, R. W., Burzykowski, T., Molenberghs, G., & Piedbois, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02528-9 · Cited by 427
Self-citationCriteria for the Validation of Surrogate Endpoints in Randomized Experiments
Buyse, M., & Molenberghs, G. (1998) · Biometrics · doi:10.2307/2533853 · Cited by 425
Self-citationMandrekar, S. J., & Sargent, D. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3701 · Cited by 404
Self-citationJackman, D. M., Miller, V. A., Cioffredi, L.-A., Yeap, B. Y., Jänne, P. A., Riely, G. J., Ruiz, M. G., Giaccone, G., Sequist, L. V., & Johnson, B. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0888 · Cited by 379
Van Cutsem, E., Lang, I., D'haens, G., Moiseyenko, V., Zaluski, J., Folprecht, G., Tejpar, S., Kisker, O., Stroh, C., & Rougier, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2 · Cited by 372
Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer
Buyse, M., Burzykowski, T., Carroll, K., Michiels, S., Sargent, D. J., Miller, L. L., Elfring, G. L., Pignon, J.-P., & Piedbois, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8836 · Cited by 354
Self-citationThe Evaluation of Surrogate Endpoints
(2005) · Statistics for Biology and Health · doi:10.1007/b138566 · Cited by 310
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
Bogaerts, J., Cardoso, F., Buyse, M., Braga, S., Loi, S., Harrison, J. A., Bines, J., Mook, S., Decker, N., Ravdin, P., et al. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0591 · Cited by 237
Self-citationPerez, E. A., Romond, E. H., Suman, V. J., Jeong, J., Davidson, N. E., Geyer, C. E., Martino, S., Mamounas, E. P., Kauffman, P. A., & Wolmark, N. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.512 · Cited by 218
Wagner, J. A., Williams, S. A., & Webster, C. J. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100017 · Cited by 201
Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation
Burzykowski, T., & Buyse, M. (2006) · Pharmaceutical Statistics · doi:10.1002/pst.207 · Cited by 200
Self-citationHayes, D. F., Trock, B., & Harris, A. L. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006197805041 · Cited by 184
Statistical evaluation of biomarkers as surrogate endpoints: a literature review
Weir, C. J., & Walley, R. J. (2006) · Statistics in Medicine · doi:10.1002/sim.2319 · Cited by 175
Ransohoff, D. F. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.04.020 · Cited by 163
Biomarker qualification pilot process at the US Food and Drug Administration
Goodsaid, F. M., & Frueh, F. W. (2007) · The AAPS Journal · doi:10.1208/aapsj0901010 · Cited by 155
Lassere, M. N. (2007) · Statistical Methods in Medical Research · doi:10.1177/0962280207082719 · Cited by 154
Clinical measurement in drug evaluation
Ellenberg, S. S. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)82386-5 · Cited by 146
Factors Predictive of Response to Hormone Therapy in Breast Cancer
Rastelli, F., & Crispino, S. (2008) · Tumori Journal · doi:10.1177/030089160809400314 · Cited by 140
Statistical challenges in the evaluation of surrogate endpoints in randomized trials
Molenberghs, G., Buyse, M. E., Geys, H., Renard, D., Burzykowski, T., & Alonso, A. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00236-2 · Cited by 131
Self-citationClinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All
Mandrekar, S. J., & Sargent, D. J. (2009) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400902802458 · Cited by 127
Self-citationCollette, L., Burzykowski, T., Carroll, K. J., Newling, D. W. W., Morris, T., & Schröder, F. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.156 · Cited by 111
Strategic paths for biomarker qualification
Goodsaid, F. M., Frueh, F. W., & Mattes, W. B. (2008) · Toxicology · doi:10.1016/j.tox.2007.12.023 · Cited by 104
Prognostic and predictive value of HER2/neu oncogene in breast cancer
Masood, S., & Bui, M. M. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10181 · Cited by 101
Clarke, M. J. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl238 · Cited by 101
Peterson, B. L., & George, S. L. (1993) · Controlled Clinical Trials · doi:10.1016/0197-2456(93)90031-8 · Cited by 99
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials
Shi, Q., & Sargent, D. J. (2009) · International Journal of Clinical Oncology · doi:10.1007/s10147-009-0885-4 · Cited by 94
Self-citationMolecular Classification of Breast Tumors: Toward Improved Diagnostics and Treatments
Sørlie, T. (2006) · Humana Press eBooks · doi:10.1385/1-59745-165-7:91 · Cited by 91
Individual- and trial-level surrogacy in colorectal cancer
Buyse, M. E., Burzykowski, T., Michiels, S., & Carroll, K. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207081864 · Cited by 86
Self-citationAssessing the Measure of a New Drug: Is Survival the Only Thing That Matters?
Sargent, D. J., & Hayes, D. F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8064 · Cited by 80
Self-citationSurrogate Marker Evaluation from an Information Theory Perspective
Alonso, A., & Molenberghs, G. (2006) · Biometrics · doi:10.1111/j.1541-0420.2006.00634.x · Cited by 72
The Biomarkers Consortium: On the Critical Path of Drug Discovery
Altar, C. A. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100471 · Cited by 72
The Value, Qualification, and Regulatory Use of Surrogate End Points in Drug Development
Lathia, C., Amakye, D. D., Dai, W., Girman, C. J., Madani, S., Mayne, J. T., MacCarthy, P., Pertel, P. E., SEMAN, L. J., Stoch, A., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.69 · Cited by 71
End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal
Allegra, C. J., Blanke, C. D., Buyse, M. E., Goldberg, R. M., Grothey, A. F., Meropol, N. J., Saltz, L. B., Venook, A. P., Yothers, G., & Sargent, D. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1368 · Cited by 69
Self-citationSurrogate and Mediating Endpoints: Current Status and Future Directions
Prentice, R. L. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn515 · Cited by 44
Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment
Benjamin, R. S., Dêbiec‐Rychter, M., Cesne, A. L., et al. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.06.003 · Cited by 39
Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan Meier Plots
Royston, P. J., Parmar, M., & Altman, D. G. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm265 · Cited by 39
Surrogate endpoint validation: statistical elegance versus clinical relevance
Green, E., Yothers, G., & Sargent, D. J. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207081863 · Cited by 32
Self-citationExploring and validating surrogate endpoints in colorectal cancer
Burzykowski, T., Buyse, M. E., Yothers, G., Sakamoto, J., & Sargent, D. J. (2008) · Lifetime Data Analysis · doi:10.1007/s10985-007-9079-4 · Cited by 28
Self-citationTowards validation of statistically reliable biomarkers
Buyse, M. E. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)70028-9 · Cited by 24
Self-citationEndpoints and surrogate endpoints in colorectal cancer: a review of recent developments
Piedbois, P., & Buyse, M. E. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32830218fe · Cited by 20
Self-citationBuyse, M. E. (2009) · International Journal of Clinical Oncology · doi:10.1007/s10147-009-0879-2 · Cited by 9
Self-citation
Cited by
Imaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.463 · Cited by 676
Key Concepts of Clinical Trials: A Narrative Review
Umscheid, C. A., Margolis, D. J., & Grossman, C. E. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2475 · Cited by 410
Prasad, V., Kim, C., Burotto, M., & Vandross, A. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.2829 · Cited by 403
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 380
Metadata
- Authors
- Buyse, M., Sargent, D. J., Grothey, A., Matheson, A., & de Gramont, A.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2010-04-06
- Volume
- 7
- Issue
- 6
- Pages
- 309-317
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W1985046983
- Cited by
- 314
- References
- 70
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.